NL-OMON43030尚未招募3 期
Prospective Follow-up Study for Patients who Completed Study ALX0681-C301 (HERCULES) to Evaluate Long-term Safety and Efficacy of Caplacizumab (Post-HERCULES) - Post-HERCULES
适应症
试验速览
- 阶段
- 3 期
- 状态
- 尚未招募
- 发起方
- Ablynx NV
- 入组人数
- 8
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •1. Completed the Final (28 day) FU visit in Study ALX0681-C301.
- •2. Is >= 18 years of age at the time of signing the informed consent form (ICF).
- •3. Provided informed consent prior to initiation of any study specific activity/procedure.
排除标准
- •1. Not being able/willing to comply with the study protocol procedures.
- •2. Currently enrolled in a clinical study with another investigational drug or device.
研究者
相似试验
进行中（未招募）
1 期
Follow-up Study for Patients who Completed Study ALX0681-C301 (Post-HERCULES)Acquired thrombotic thrombocytopenic purpura (TTP)MedDRA version: 20.0Level: PTClassification code 10043648Term: Thrombotic thrombocytopenic purpuraSystem Organ Class: 10005329 - Blood and lymphatic system disordersEUCTR2016-001503-23-ATAblynx NV104
进行中（未招募）
1 期
Follow-up Study for Patients who Completed Study ALX0681-C301 (Post-HERCULES)EUCTR2016-001503-23-GBAblynx NV104
进行中（未招募）
1 期
Follow-up Study for Patients who Completed Study ALX0681-C301 (Post-HERCULES)Acquired thrombotic thrombocytopenic purpura (TTP)MedDRA version: 20.0Level: PTClassification code 10043648Term: Thrombotic thrombocytopenic purpuraSystem Organ Class: 10005329 - Blood and lymphatic system disordersEUCTR2016-001503-23-CZAblynx NV104
进行中（未招募）
1 期
Follow-up Study for Patients who Completed Study ALX0681-C301 (Post-HERCULES)Acquired thrombotic thrombocytopenic purpura (TTP)MedDRA version: 20.0Level: PTClassification code 10043648Term: Thrombotic thrombocytopenic purpuraSystem Organ Class: 10005329 - Blood and lymphatic system disordersEUCTR2016-001503-23-NLAblynx NV92
进行中（未招募）
1 期
Follow-up Study for Patients who Completed Study ALX0681-C301 (Post-HERCULES)EUCTR2016-001503-23-FRAblynx NV92